73.6 Gy and beyond: Hyperfractionated accelerated radiotherapy for non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 19, Issue 3, 2001, Pages 705-711

  Maguire, P D ^a   Marks, L B ^a   Sibley, G S ^a   Herndon II, J E ^a   Clough, R W ^a   Light, K L ^a   Hernando, M L ^a   Antoine, P A ^a   Anscher, M S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; ESOPHAGUS DISEASE; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION HAZARD; SKIN TOXICITY; TECHNIQUE;

EID: 0035253722     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.3.705     Document Type: Article

References (26)

1. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with ≥ 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small cell lung carcinoma - Report of Radiation Therapy Oncology Group 83-11
2. Improved survival of stage III non-small cell lung cancer: Seven-year follow-up Cancer and Leukemia Group B (CALGB) 8433 trial
3. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer
4. Radiotherapy alone vs combined chemotherapy and radiotherapy in non-resectable non-small cell lung cancer: First analysis of a randomized trial in 353 patients
5. Cisplatin-based chemotherapy (CT) in patients with locally advanced non-small cell lung cancer (NSCLC): Late analysis of a French randomized trial
6. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radio-therapy in non-small cell lung cancer: A randomized, multi-center trial
7. Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small cell lung cancer: Results of Eastern Cooperative Oncology Group 4593
8. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: Unusual toxicity and promising early results
9. Using plasma TGF-beta as a marker to select patients for radiotherapy dose escalation
10. Nonparametric estimation from incomplete observations
11. Results of radical radiation therapy in clinical stage I, technically inoperable non-small cell lung cancer
12. Radiation therapy in the management of medically inoperable carcinoma of the lung: Results and implications for future treatment stategies
13. Radiotherapy alone for medically inoperable lung cancer: The Duke experience
14. A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers
15. The treatment of stage III nonsmall cell lung cancer using high dose conformal radiotherapy
16. Results of high-dose thoracic irradiation incorporating beam's eye view display in non-small cell lung cancer: A retrospective multivariate analysis
17. Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer
18. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer
19. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study
20. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancer: Radiation Therapy Oncology Group protocol 91-06
21. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable non-small cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04
22. A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Ind CT) and concomitant chemotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC)
23. Carboplatin/Taxol (C/T) or carboplatin/Navelbine (C/N) followed by accelerated hyperfractionated conformal radiation therapy (RT) to >73:6 Gy. A phase i-ii dose escalation study from the Carolina 3D Consortium
24. Clinical and dosimetric predictors of radiation-induced esophageal toxicity
25. Physical and biologic predictors of changes in whole lung function following thoracic irradiation
26. Plasma transforming growth factor beta b1 as a predictor of radiation pneumonitis